Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Rezolute, Inc., a rare disease biopharmaceutical company, announced that results from its Phase 3 sunRIZE study evaluating ersodetug in treating congenital hyperinsulinism (HI) will be presented at the Pediatric Endocrine Society Annual Meeting. The study showed promising therapeutic benefits of ersodetug, an antibody designed to reduce hypoglycemi…